Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Long-Term Risk for CVD Stratified by Fasting Glucose Level

By LabMedica International staff writers
Posted on 31 Jan 2019
Cardiovascular disease (CVD) refers to any disease of the heart, vascular disease of the brain, or disease of the blood vessel. The most prevalent cardiovascular diseases include coronary heart disease (CHD) such as a heart attack and cerebrovascular disease such as a stroke.

Middle-aged adults who experience an increase in fasting glucose level into the range for diabetes have an elevated 30-year risk for coronary heart disease and stroke compared with their peers with normal blood glucose levels. It has also been reported that an increased long-term CVD risk for middle-aged men with fasting glucose in the prediabetes range.

Scientists at Wake Forest School of Medicine (Winston-Salem, NC, USA) and their colleagues pooled data from seven observational cohorts that included both white and black adults. They estimated the long-term risk for CVD based on fasting glucose levels both below and above the threshold for diabetes (7 mmol/L or 126 mg/dL). Combined, the seven cohorts followed participants from 1960 to 2015. A total of 19,630 participants (56.1% women; 31.6% black) at an index age of 55 years were included. The team created five stratifications for fasting glucose levels: less than 5 mmol/L, between 5 mmol/L and 5.5 mmol/L, between 5.6 mmol/L and 6.2 mmol/L, between 6.3 mmol/L and 6.9 mmol/L (prediabetes) and more than 7 mmol/L (diabetes). CVD was defined as CHD, myocardial infarction and fatal and nonfatal stroke.

The investigators reported that the risk for CVD through 85 years of age ranged from 15.3% (<5.0 mmol/L) to 38.6% (diabetes levels) among women and from 21.5% (5.0–5.5 mmol/L) to 47.7% (diabetes levels) among men. A fasting glucose (FG) of 6.3–6.9 mmol/L was associated with higher long-term CVD risk compared with the lowest FG among men, but not women. Increases in glucose during midlife with conversion to diabetes were associated with higher cardiovascular risk (1.3- to 3.6-fold) than when increasing glucose below the diabetes threshold.

Michael P. Bancks, PhD, an assistant professor of Endocrinology and lead author of the study said, “The study shows the importance of preventing or delaying the development of diabetes in order to prevent the development of cardiovascular disease. Our study included a large number of African-Americans and people from geographically diverse areas of the USA, so our findings can be generalized to a much broader USA audience than the prior work.” The study was published in the January 2019 issue of the journal Diabetes Care.

Related Links:
Wake Forest School of Medicine


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.